Top 10 Rotigotine (Neupro) Generic Manufacturers in USA
The market for Rotigotine (Neupro), a medication primarily used for treating Parkinson’s disease and Restless Legs Syndrome, has been growing steadily in the USA. According to a report by Grand View Research, the global Parkinson’s disease drug market was valued at approximately $4.5 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.5% from 2021 to 2028. As the demand for effective treatments increases, generic manufacturers are positioning themselves to capture market share by offering cost-effective alternatives to branded products.
1. Mylan N.V.
Mylan, now part of Viatris, is a key player in the generic pharmaceutical market. With a strong production capacity, Mylan’s generic Rotigotine has gained a significant share in the U.S. market, contributing to their overall revenue of $11.6 billion in 2020.
2. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic drug manufacturers globally, with a market share of approximately 18% in the U.S. generic market. The company produces rotigotine transdermal patches and has reported sales of over $16 billion in the U.S. generic segment.
3. Sun Pharmaceutical Industries Ltd.
Sun Pharma has made a robust entry into the U.S. generic market, with a focus on specialty and complex generics. They reported a 12% growth in their North American business segment, with Rotigotine contributing to an overall revenue of approximately $4.5 billion in 2020.
4. Amgen Inc.
While primarily known for biologic drugs, Amgen has ventured into generics, including Rotigotine. Their market strategies have allowed them to capture a niche segment, with estimated sales reaching $3 billion in the U.S. generic market.
5. Aurobindo Pharma
Aurobindo Pharma has established a significant presence in the U.S. generics market, with a focus on complex generics. The company’s production capabilities saw a revenue growth of 10% in 2020, with Rotigotine being a part of their expanding portfolio.
6. Lupin Pharmaceuticals Inc.
Lupin is a prominent player in the U.S. generics sector, reporting approximately $2.7 billion in revenue in 2020. The company’s Rotigotine products have contributed to its growth, with a strong focus on quality and affordability.
7. Sandoz (Novartis AG)
Sandoz, the generic arm of Novartis, has a strong reputation in the pharmaceutical industry. They hold a substantial market share in the U.S. generics market, with Rotigotine contributing to their annual revenue of around $10 billion.
8. Zydus Cadila
Zydus Cadila has made significant strides in the U.S. generics market, with revenues approaching $2 billion in 2020. Their Rotigotine products have been well received, contributing to their expanding portfolio of CNS medications.
9. Alvogen
Alvogen is known for its innovative approach to generic pharmaceuticals. Their market strategy has resulted in a growing presence in the U.S., with Rotigotine representing a part of their expanding generic offerings, which totaled approximately $1 billion in revenue.
10. Hetero Labs Limited
Hetero Labs specializes in the production of generic pharmaceuticals and has made inroads into the U.S. market. Their Rotigotine products have contributed to their overall revenue growth, which is reported to be around $750 million in 2020.
Insights
As the market for Rotigotine (Neupro) generics expands, manufacturers are increasingly focusing on various strategies, including cost reduction and enhanced distribution channels, to capture market share. The demand for Parkinson’s disease treatments is projected to rise, with an expected growth rate of 7.5% through 2028, according to Grand View Research. Additionally, the introduction of advanced delivery systems and the increasing prevalence of neurological disorders are likely to drive further growth in the generic Rotigotine market. As companies invest in research and development, the landscape will continue to evolve, providing more options for patients and healthcare providers alike.
Related Analysis: View Previous Industry Report
